低剂量纳曲酮治疗活检证实的甲扁平苔藓
本病例系列纳入7例活检证实的成人甲扁平苔藓患者,每日口服低剂量纳曲酮3 mg,治疗2至11个月;4例临床有效,甲扁平苔藓严重指数总体降低35%,2例重度转为轻度,未报告不良事件。作者认为低剂量纳曲酮可能为甲扁平苔藓的治疗选择,需进一步对照研究验证。
要点
- 7例活检证实的甲扁平苔藓患者接受低剂量纳曲酮3 mg/日治疗。
- 4/7例临床有效,严重指数总体降低35%,2例重度转为轻度。
- 未因不良事件停药,未报告不良事件。
核心结论
- 低剂量纳曲酮可能成为甲扁平苔藓的治疗选择。
- 需进一步对照研究以明确其临床疗效与安全性。
研究设计与样本
- 病例系列研究,纳入7例活检证实的成人甲扁平苔藓患者。
- 低剂量纳曲酮剂量为3 mg/日,治疗至少2个月并有面诊随访。
主要发现
- 7例患者平均年龄60岁(范围38-77岁),其中3例女性。
- 除1例外,其余患者既往至少1种治疗无效(中位治疗数2.5,范围0-4.0)。
- 治疗时长2至11个月。
- 4/7例观察到临床应答,甲扁平苔藓严重指数总体降低35%。
- 2例重度患者降至轻度;未报告不良事件,无患者因不良事件停药。
关键数值与推荐
- 主要结局为治疗后临床甲扁平苔藓严重指数,评分为清除、轻度、中度或重度。
- 治疗期间评估口腔与皮肤病变,并记录耐受性与不良事件。
临床怎么用
- 对于活检证实的甲扁平苔藓,尤其既往治疗无效者,可考虑低剂量纳曲酮3 mg/日。
- 治疗期间应评估甲、口腔及皮肤病变,并监测耐受性与不良事件。
局限性
- 为病例系列研究,样本量小(7例),无对照组。
- 原文未报告随机化、盲法或统计学比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Nail lichen planus has the potential to cause permanent destruction of the nail unit and remains challenging to treat. Studies suggest that low-dose naltrexone is a safe and potentially effective treatment for other dermatologic conditions, including lichen planopilaris. OBJECTIVE: To assess the effectiveness of low-dose naltrexone in treating nail lichen planus. DESIGN, SETTING, AND PARTICIPANTS: This case series evaluates 7 adult patients with biopsy-proven nail lichen planus who were treated with low-dose naltrexone (3 mg per day) at the University of Miami dermatologic clinics from November 2022 to December 2023. The data were analyzed in March 2024. Patients were treated for at least 2 months and had in-person follow-up evaluation while receiving treatment. MAIN OUTCOMES AND MEASURES: The main outcome was posttreatment clinical nail lichen planus severity index, which was scored as clear, mild, moderate, or severe. Patients were evaluated for oral and cutaneous disease during the course of treatment. Tolerance and adverse events were noted. RESULTS: A total of 7 patients (mean [range] age, 60 [38-77] years; 3 female individuals) were included. All but 1 patient had been previously treated and did not respond to at least 1 prior treatment (median [range], 2.5 [0-4.0] treatments). Treatment duration ranged from 2 to 11 months. Clinical response was observed in 4 of 7 patients, with an overall 35% reduction in nail lichen planus severity index. Two patients with severe disease achieved a reduction to mild severity. None of the patients had to discontinue low-dose naltrexone due to adverse events, and no adverse events were reported. CONCLUSIONS AND RELEVANCE: The results of this study suggest that low-dose naltrexone may be a therapeutic approach for treating nail lichen planus. Further controlled studies are warranted to better understand its clinical efficacy and safety profile in treating nail lichen planus.
引用
- Bray ER, Morrison BW. Low-Dose Naltrexone Use in Biopsy-Proven Lichen Planus of the Nails. JAMA Dermatol. 2024. PMID: 39475878. doi:10.1001/jamadermatol.2024.4098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。